Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2017-07-30
Target enrollment:
Participant gender:
Summary
This study consists of two parts. In a phase Ib part, investigators will explore the
recommended dose of gemcitabine, cisplatin, and RAD001 combination in patients with
metastatic TNBC. After completing the phase Ib part, investigators will review the data and
discuss with Novartis before the start of a phase II part. In the phase II part,
investigators will compare the efficacy of the gemcitabine and cisplatin with or without
RAD001 in patients with metastatic TNBC.